NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
0.3430
Dollar change
+0.0051
Percentage change
1.51
%
Index- P/E- EPS (ttm)-1.08 Insider Own31.65% Shs Outstand67.01M Perf Week-3.41%
Market Cap22.99M Forward P/E- EPS next Y-1.07 Insider Trans1.00% Shs Float45.82M Perf Month-13.99%
Enterprise Value-46.99M PEG- EPS next Q-0.28 Inst Own54.39% Short Float4.11% Perf Quarter-7.35%
Income-71.93M P/S0.94 EPS this Y45.62% Inst Trans-12.90% Short Ratio2.67 Perf Half Y-67.64%
Sales24.56M P/B0.31 EPS next Y0.77% ROA-29.53% Short Interest1.88M Perf YTD-67.64%
Book/sh1.09 P/C0.15 EPS next 5Y24.37% ROE-70.06% 52W High3.65 -90.60% Perf Year-86.65%
Cash/sh2.35 P/FCF- EPS past 3/5Y2.26% -8.30% ROIC-47.49% 52W Low0.30 14.18% Perf 3Y-94.64%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin80.64% Volatility11.88% 9.37% Perf 5Y-98.43%
Dividend TTM- EV/Sales-1.91 EPS Y/Y TTM57.85% Oper. Margin-296.47% ATR (14)0.03 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.43 Sales Y/Y TTM146.47% Profit Margin-292.92% RSI (14)45.20 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio8.43 EPS Q/Q80.31% SMA20-6.78% Beta2.64 Target Price6.50
Payout- Debt/Eq1.19 Sales Q/Q114.91% SMA50-10.94% Rel Volume0.96 Prev Close0.34
Employees115 LT Debt/Eq1.07 EarningsMay 07 AMC SMA200-67.29% Avg Volume705.79K Price0.34
IPOJun 12, 2020 Option/ShortYes / Yes EPS/Sales Surpr.23.24% 309.43% Trades Volume676,584 Change1.51%
Date Action Analyst Rating Change Price Target Change
Oct-19-23Downgrade TD Cowen Outperform → Market Perform
Nov-08-22Initiated Canaccord Genuity Buy $9
Dec-14-21Downgrade William Blair Outperform → Mkt Perform
Jun-08-21Initiated JMP Securities Mkt Outperform $40
Feb-24-21Initiated William Blair Outperform
Feb-18-21Initiated Needham Buy $50
Jul-07-20Initiated Wedbush Outperform $31
Jul-07-20Initiated JP Morgan Overweight $28
Jul-07-20Initiated Jefferies Buy $38
Jul-07-20Initiated Cowen Outperform
May-28-25 06:59AM
May-07-25 05:35PM
04:05PM
Apr-02-25 06:59AM
Mar-13-25 05:15PM
04:05PM Loading…
04:05PM
Feb-24-25 06:59AM
Jan-06-25 04:30PM
Nov-06-24 05:40PM
04:05PM
Oct-22-24 06:59AM
Sep-12-24 04:05PM
Aug-07-24 11:54PM
07:35PM
04:05PM
06:59AM Loading…
Aug-06-24 06:59AM
Jun-14-24 06:59AM
Jun-03-24 04:30PM
04:17PM
May-25-24 11:10PM
May-13-24 09:54PM
05:15PM
04:05PM
May-09-24 06:59AM
May-04-24 10:49AM
Apr-22-24 05:31PM
Apr-02-24 06:59AM
Mar-08-24 04:32AM
Mar-06-24 10:52PM
05:40PM
04:20PM Loading…
04:20PM
Feb-27-24 06:59AM
Jan-03-24 04:05PM
Dec-06-23 03:05AM
Nov-29-23 08:41AM
06:59AM
Nov-09-23 04:15PM
Oct-26-23 06:59AM
Oct-18-23 06:59AM
Sep-19-23 07:30AM
Aug-03-23 08:49AM
07:30AM
Aug-02-23 07:05PM
04:15PM
May-31-23 07:30AM
May-10-23 06:05PM
04:15PM
May-09-23 04:15PM
Apr-11-23 07:30AM
Apr-10-23 09:40AM
Apr-05-23 07:30AM
Mar-24-23 03:02PM
Mar-23-23 10:43AM
07:29AM
07:00AM
Mar-21-23 04:15PM
Feb-27-23 07:30AM
Feb-24-23 07:18AM
Feb-23-23 04:28PM
Jan-03-23 04:30PM
Dec-05-22 09:55AM
Nov-17-22 09:55AM
Nov-03-22 04:15PM
Nov-01-22 08:07AM
Sep-22-22 07:30AM
Sep-20-22 07:30AM
Sep-17-22 08:12AM
Aug-04-22 05:45PM
04:15PM
Aug-02-22 04:15PM
Jul-18-22 07:30AM
Jul-11-22 09:55AM
Jun-21-22 08:30AM
Jun-02-22 07:30AM
May-25-22 06:37AM
May-05-22 07:05PM
04:15PM
Apr-05-22 07:30AM
Mar-25-22 12:00PM
10:00AM
Mar-02-22 07:30AM
Feb-24-22 04:20PM
Feb-10-22 07:30AM
Jan-05-22 07:30AM
Dec-28-21 07:37PM
Dec-19-21 09:37PM
Dec-16-21 11:02PM
06:38PM
07:01AM
Dec-14-21 06:30AM
12:38AM
Nov-10-21 04:20PM
Oct-22-21 07:30AM
Oct-21-21 04:05PM
Oct-15-21 07:30AM
Sep-30-21 11:12AM
Sep-17-21 08:34AM
Aug-11-21 04:20PM
Aug-03-21 07:30AM
Jul-14-21 07:30AM
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quinn Anthony G.DirectorJan 10 '25Buy0.96125,791120,759214,286Jan 14 04:05 PM
Quinn Anthony G.DirectorJan 13 '25Buy0.9785,00082,450299,286Jan 14 04:05 PM
Howze YalondaCHIEF LEGAL OFFICEROct 15 '24Option Exercise2.423,3478,10015,169Oct 17 04:05 PM